Literature DB >> 24958943

Medication safety and pharmacovigilance resources for the ambulatory care setting: enhancing patient safety.

Jennifer A Gershman1, Andrea D Fass1.   

Abstract

Reputable medication safety resources are fundamental to assist in reducing medication errors and educating consumers. The purpose of this article is to describe medication safety and pharmacovigilance electronic and mobile resources that are available to pharmacists to enhance patient safety in the ambulatory care setting at the national level through the US Food and Drug Administration (FDA), Drug Enforcement Administration (DEA), American Medicine Chest Challenge, and Institute for Safe Medication Practices (ISMP). Information concerning drug disposal methods is available through the FDA, DEA, and the American Medicine Chest Challenge Rx Drop app. The ISMP provides a variety of tools for reporting and preventing medication errors including Assess-ERR and ConsumerMedSafety.org. Risk Evaluation and Mitigation Strategies (REMS) were created as a requirement of the FDA Amendments Act of 2007 to ensure that the drug's benefits outweigh the risks. Health care professionals are encouraged to report adverse drug events through the FDA's MedWatch reporting system. Pharmacists have a variety of useful resources for their medication safety and pharmacovigilance toolbox. Studies should evaluate the use of these resources by pharmacists and consumers.

Entities:  

Keywords:  electronic resources; medication safety; mobile resources; pharmacovigilance

Year:  2014        PMID: 24958943      PMCID: PMC4062749          DOI: 10.1310/hpj4904-363

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  7 in total

Review 1.  Risk evaluation and mitigation strategies (REMS): educating the prescriber.

Authors:  Susan C Nicholson; Janet Peterson; Behin Yektashenas
Journal:  Drug Saf       Date:  2012-02-01       Impact factor: 5.606

2.  Pharmaceuticals in drinking water: local analysis of the problem and finding a solution through awareness.

Authors:  Julie Ehret Leal; Amy N Thompson; Walter A Brzezinski
Journal:  J Am Pharm Assoc (2003)       Date:  2010 Sep-Oct

3.  Program seeks to enlist physicians to flag questionable promotion of drugs.

Authors:  Mike Mitka
Journal:  JAMA       Date:  2010-07-07       Impact factor: 56.272

4.  Pediatric information in drug product labeling.

Authors:  Aaron N Sachs; Debbie Avant; Catherine S Lee; William Rodriguez; M Dianne Murphy
Journal:  JAMA       Date:  2012-05-09       Impact factor: 56.272

5.  The FDA Bad Ad Program: implications for NPs.

Authors:  Jennifer A Fass
Journal:  Nurse Pract       Date:  2011-04

6.  Prescription drug take-back programs.

Authors:  Jennifer A Fass
Journal:  Am J Health Syst Pharm       Date:  2011-04-01       Impact factor: 2.637

7.  Texas pharmacists' knowledge of reporting serious adverse drug events to the Food and Drug Administration.

Authors:  Paul Gavaza; Carolyn M Brown; Kenneth A Lawson; Karen L Rascati; James P Wilson; Mary Steinhardt
Journal:  J Am Pharm Assoc (2003)       Date:  2011 May-Jun
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.